Purpose of this Study
We are doing this study to find the best dose of the study drug, ABBV-400, and to see if it is a safe and effective option for treating cancer.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with an advanced form of cancer
- Have not seen improvement from standard therapies
For more information about who can join this study, please contact the study team at 919-668-1861.
- Are diagnosed with an advanced form of cancer
- Have not seen improvement from standard therapies
For more information about who can join this study, please contact the study team at 919-668-1861.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will:
- Get IV infusions of the study drug every 3 weeks for up to 2 years
- Give blood and urine samples
- Have regular CT or MRI scans
- Get IV infusions of the study drug every 3 weeks for up to 2 years
- Give blood and urine samples
- Have regular CT or MRI scans
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
[M21-404] A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00111582
NCT ID
NCT05029882
Phase
I
Enrollment Status
OPEN TO ACCRUAL